Full Paper
D-(+)-iso-Methanocarbathymidine: a High-Affinity Substrate for Herpes Simplex Virus 1 Thymidine Kinase
Article first published online: 9 APR 2008
DOI: 10.1002/cmdc.200800027
Copyright © 2008 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
Additional Information
How to Cite
Comin, Maria J., Vu, B. Christie., Boyer, Paul L., Liao, C., Hughes, Stephen H. and Marquez, Victor E. (2008), D-(+)-iso-Methanocarbathymidine: a High-Affinity Substrate for Herpes Simplex Virus 1 Thymidine Kinase. ChemMedChem, 3: 1129–1134. doi: 10.1002/cmdc.200800027
Publication History
- Issue published online: 8 JUL 2008
- Article first published online: 9 APR 2008
- Manuscript Revised: 11 MAR 2008
- Manuscript Received: 31 JAN 2008
Funded by
- NIH
- Center for Cancer Research
- NCI-Frederick
Keywords:
- antiviral agents;
- asymmetric synthesis;
- carbocyclic nucleosides;
- enantiomers;
- HSV thymidine kinase
Abstract
The stereoselective syntheses of the (+)-D and (−)-L enantiomers of iso-methanocarbathymidine (iso-MCT) was achieved through two independent linear approaches that converged on two antipodal enantiomers, common to a key precursor used in the synthesis of racemic iso-MCT. In the study reported herein we identified (+)-3 [D-(+)-iso-MCT] as the active enantiomer that was exclusively recognized by the herpes simplex virus 1 thymidine kinase (HSV1-tk), as was predicted by molecular modeling. For this purpose, a human osteosarcoma (HOS) cell line modified to contain and express HSV1-tk from herpes simplex virus 1 (HSV1) was used to determine the cytotoxicity of the compounds by an assay that measures the level of ATP in the cells. The work demonstrates that changes in the substitution pattern of rigid bicyclo[3.1.0]hexane nucleosides, which, relative to normal nucleosides, appear unconventional, can lead to the spatial optimization of pharmacophores and vastly improved substrate recognition.

1860-7187/asset/2452_left.gif?v=1&s=4110e7425ac5e40773dfb0778cfefa62f1594507)
1860-7187/asset/2452_right.gif?v=1&s=8458ea1f15af84217b579501ed7d7733bef04a94)
